B+
Bull case
20%
Probability
Target price
$23.10
+45.5% vs current
NPCE
NeuroPaceCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$18.80
+18.4% vs current
B-
Bear case
20%
Probability
Target price
$15.00
-5.5% vs current
AI sentiment snapshot
Latest data as of 2026-01-17
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+65.9
Score
AI commentary
Aggregated analyst targets sit modestly above the current price (median 18.8 vs. anchor 16.94), implying cautious upside from consensus [#SERP-2]. Dispersion (15.0–23.1) reflects uncertainty on adoption and reimbursement; near-term sentiment will hinge on earnings, payer updates, and clinical readouts [#SERP-4][#SERP-7].
RankAlpha Sentiment AI - 2026-01-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-17catalystNext quarterly earnings / guidance updateHigh impact
Upcoming quarterly report assumed within 90 days (used conservative date); market reaction likely to depend on implant volumes and FY guidance — assumption and estimate used in modeling (date estimate) [#SERP-4].
2026-12-31eventClinical readout / adoption milestone (assumed window)High impact
Assumed clinical or adoption milestone window through H2 2026; selected window end as the expected_date and noted assumption — outcome could drive medium-sized re-rating [#SERP-7].
2027-01-17catalystReimbursement / label expansion for the RNS systemHigh impact
Broader payer coverage or label/reimbursement wins would materially expand addressable market over multiple quarters; conservative 12‑month-plus timing used for long scenario [#SERP-1].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-17 • Updated nightlySource: Internal modelMethodology